Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

Pelareorep plus chemotherapy with or without Tecentriq had an acceptable safety profile in patients with newly diagnosed ...

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

The pooled prevalence of chronic painful neuropathy is 41.22 percent among individuals with chemotherapy-induced peripheral neuropathy.

WEDNESDAY, Jan. 29, 2025 (HealthDay News) -- Four in every 10 cancer patients treated with chemotherapy develop severe ...

Very sick patients who get a bone marrow transplant at Medical University of South Carolina survive at a much higher rate ...

SAN ANTONIO — Texas Oncology – San Antonio teamed up with Angeles Sin Fronteras to provide free wigs and cosmetic kits to ...

The pooled prevalence of chronic painful neuropathy is 41.22 percent among individuals with chemotherapy-induced perip ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new evidence review suggests. These patients might experience loss of balance and coordination ...

Managing maximum tolerated dose (MTD) chemotherapy while minimizing neutropenia relies on precise complete blood count (CBC) monitoring and AI-powered diagnostics.

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...